Thor-Henrik Brodtkorb
2PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (2)
Sort by Publication Date:
|Mar 12, 2024
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar
|Feb 22, 2024
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo.Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt
Pageof 1
